Stephen T. Keir

Duke University — United States

Medicine · Health Sciences

56h-index15.5kcitations350works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(75), Monoclonal and Polyclonal Antibodies Research(63), Neuroblastoma Research and Treatments(47), Immunotherapy and Immune Responses(39), Cancer therapeutics and mechanisms(35)

Publications348 total

DNAR-07. SMARCAL1 inhibition synergizes with TOP1 inhibitors to induce replication catastrophe and inflammation in ALT+ gliomas
Neuro-Oncology·2025Open Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
Scientific Reports·2025· 1 citedOpen Access
OS05.2.A DECIPHERING THE LONGITUDINAL TRAJECTORIES OF GLIOBLASTOMA ECOSYSTEMS BY INTEGRATIVE SINGLE-CELL GENOMICS
Neuro-Oncology·2025Open Access
Supplementary Figure S3 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Supplementary Figure S5 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Supplementary Figure S2 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Data from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Supplementary Figure S1 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Supplementary Figure S4 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
2025Open Access
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics
Nature Genetics·2025· 36 citedOpen Access
The multilayered transcriptional architecture of glioblastoma ecosystems
Nature Genetics·2025· 46 citedOpen Access
Abstract 6872: Repurposing the DNA labeling agent EdU for glioblastoma treatment
Cancer Research·2025
Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
Molecular Cancer Therapeutics·2025· 4 citedOpen Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
2025Open Access
EPCO-34. DECIPHERING THE LONGITUDINAL TRAJECTORIES OF GLIOBLASTOMA BY INTEGRATIVE SINGLE-CELL GENOMICS
Neuro-Oncology·2024Open Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8 <sup>+</sup> infiltration in glioma
2024Open Access
Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
2024Open Access
Figure S4 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
2024Open Access
Figure S15 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
2024Open Access
Supplementary Tables S1-S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
2024Open Access
page 1 of 18Next →

Frequent Co-authors

Peter J. Houghton(25), Darell D. Bigner(23), E. Anders Kolb(22), C. Patrick Reynolds(22), John M. Maris(22), Malcolm A. Smith(22), Richard Görlick(20), Richard B. Lock(20), Christopher L. Morton(17), Hernán Carol(16), Min H. Kang(13), Henry S. Friedman(12), Roger E. McLendon(11), Catherine A. Billups(11), Jianrong Wu(10), Hai Yan(6), Raushan T. Kurmasheva(5), David A. Reardon(4), Jeremy N. Rich(4), Gary L. Gallia(3)